Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Alembic Pharmaceuticals Ltd Performance

Today's Low
977.75
arrowIcon
Today's High
1,004.85
52 Wk Low
517.05
arrowIcon
52 Wk High
1,094.00


Open

986

Traded Value (Cr)

9.10 Cr

Prev. Close

993.75

VWAP

990.79

Volume

77,497

Face Value

2

Alembic Pharmaceuticals Ltd Fundamentals

Market Cap
₹ 19,513 Cr
P/E Ratio (TTM)
33.06
P/B Ratio
4.37
Debt to Equity
0.19
ROE
11.89 %
EPS (TTM)
30.03
Dividend Yield
0.81%
Book Value
227.41

Click here to know more about Fundamentals

Alembic Pharmaceuticals Ltd Financials

Alembic Pharmaceuticals Ltd Financials

Alembic Pharmaceuticals Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 69.61 % 69.61 % 69.61 % 69.61 %
Others 10.70 % 10.17 % 10.32 % 10.43 %
Mutual Funds 7.82 % 7.71 % 7.33 % 6.64 %
Retail 7.41 % 8.00 % 8.24 % 8.98 %
FII 4.46 % 4.52 % 4.50 % 4.34 %

Promoters

69.61%

Others

10.70%

Mutual Funds

7.82%

Retail

7.41%

FII

4.46%

Promoters

69.61%

Others

10.17%

Mutual Funds

7.71%

Retail

8.00%

FII

4.52%

Promoters

69.61%

Others

10.32%

Mutual Funds

7.33%

Retail

8.24%

FII

4.50%

Promoters

69.61%

Others

10.43%

Mutual Funds

6.64%

Retail

8.98%

FII

4.34%

Resistance and Support

₹958.33

PIVOT

resistance-arrow
Resistance
First Resistance₹966.667
Second Resistance₹975.933
Third Resistance₹984.267
support-arrow
Support
First Resistance₹949.067
Second Resistance₹940.733
Third Resistance₹931.467
RSI62.632
MACD21.828
ADX20.803
CCI34.047

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day77,49738,85041.97
Week138,64863,44458.96
1 Month124,75365,60152.72
6 Months77,49743,24455.80

About Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals manufactures and markets generic pharmaceutical products all over the world. The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Ltd was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in pharmaceuticals business. As per the scheme of arrangement, the 'Pharmaceutical Undertaking' of the Alembic Ltd was demerged and transferred to the company with effect from appointed date, April 1, 2010. In April 15, 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement. The shareholding of Alembic Ltd in the company reduced from 100% to 29.18%. Thus, the company became an associate of Alembic Ltd. In September 20, 2011, the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange. During 2012, Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiq). The company enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. During 2013, the company got USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA. During 2014, the company announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A.'. During 2015, the company's associate signs exclusive agreement with Novartis. During the year, the company launched Aripiprazole on Day-1. Also during the year, the company transitioned to own marketing in the US. In 2016, the company formed 60:40 joint venture with Orbicular viz. Aleor Dermaceuitical Limited for developing Dermatology Products for international markets. In July 2017, Alembic Pharmaceuticals inaugurated a state of the art anti-cancer manufacturing facility at Panelav, Halol, Gujarat. The plant has an initial manufacturing capacity of 60 million tablets/capsules and approximate 20 million vials of liquid injectable and lyophilized concentrates. Alembic will commence exporting oncology products from the new plant to US, Middle East, North Africa, Australia and South Africa. On 1 November 2017, Alembic Pharmaceuticals announced that through its 100% owned subsidiary, Alembic Pharmaceuticals Inc., it has completed acquisition of West Caldwell, New Jersey, USA based generic drug developer Orit Laboratories LLC along with real estate, owned by Okner Realty LLC. Orit has seven approved ANDAs and four ANDAs pending approval. With a state-of-the-art 8,600 square feet R&D and pilot manufacturing facility, Orit is focused on developing and filing oral solid and liquid products. Apart from existing ANDAs, Orit adds complementary skill sets in soft gelatin based oral solids and oral liquids to Alembic with a team of eight highly experienced scientists. On 21 March 2018, Alembic Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) conducted an inspection at the company's formulation facility located at Panelav, Gujarat from 12 March to 20 March 2018. This was a scheduled inspection and at the end of the inspection, the US FDA issued a Form 483 with 3 observations. None of the observations are related to data integrity or repetitive in nature. The company is preparing the response to the observations, which will be submitted to the US FDA shortly. On 24 April 2018, Alembic Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) conducted an inspection at Alembic Pharmaceuticals API Facility located at Panelav from 16 April 2018 to 23 April 2018. This was a scheduled inspection and at the end of the inspection, there were zero 483s. In 2019, the Company launched 9 new products in the US. In 2021, Rhizen's out-licenced, novel molecule 'Umbralicib (UKONIQ)' was launched by TG Therapeutics USA. During the year 2021-22, the Company acquired the balance 40% stake held by the joint venture partner in Aleor Dermaceuticals Limited (Aleor) and pursuant to said acquisition, Aleor became a wholly owned subsidiary of the Company. The Scheme of Arrangement for amalgamation of Aleor Dermaceuticals Limited, wholly owned subsidiary with the Company and their respective shareholders was made effective from 29th August, 2022. During FY23, the Company filed 20 ANDAs and received approvals for 22 ANDAs taking the total filed ANDAs to 245 as on March 31, 2023. At Panelav, Alembic set up dedicated blocks (F2) for manufacturing oncology products which was approved by the US FDA in 2022. The Company launched various new products, especially in the gynecology and anti-diabetic spaces; it launched 33 new SKUs in FY23, of which 66% were in specialty therapies. It established a subsidiary in Chile to gain a strong foothold in the large and growing Latin American markets. It opened a scientific office in the UAE to capitalise on the opportunities emerging from the GCC nations.

Managing Director

Pranav Amin

Founded

2010

NSE Symbol

APLLTD

Alembic Pharmaceuticals Ltd Management

NameDesignation
Chirayu R AminChairman & CEO
Pranav N ParikhIndependent Director
K G RamanathanIndependent Director
Paresh SaraiyaIndependent Director
Rajkumar BahetiDirector (Finance) & CFO
Pranav AminManaging Director
Shaunak AminManaging Director
Archana HingoraniIndependent Director
Ashok BaratIndependent Director
Manisha SarafCompany Sec. & Compli. Officer
Jai S DiwanjiIndependent Director

Alembic Pharmaceuticals Ltd News

Alembic Pharma rises on USFDA nod for breast cancer drug
Alembic Pharmaceuticals advanced 2.94% to Rs 1,011.20 after it received tentative approval from the US Food & Drug Administration (US FDA) for Ribociclib tablets.
Alembic Pharmaceuticals receives USFDA tentative approval for Ribociclib Tablets
Alembic Pharma's oncology formulation facility undergoes USFDA audit
Alembic Pharma’s Gujarat facility gets 4 observations from USFDA
Alembic Pharmaceutical said that USFDA had conducted inspection at its oncology (injectable and oral solid) formulation facility (F-2) at Panelav,Gujarat.
CRISIL reaffirms ratings of Alembic Pharmaceuticals with 'stable' outlook
Alembic Pharmaceuticals said that CRISIL Ratings has reaffirmed its 'CRISIL AA+/Stable/CRISIL A1+’ ratings on the bank loan facilities and commercial paper programme of the company.
Alembic Pharma records 48% growth in Q3 PAT
The drug maker recorded 48.01% jump in consolidated net profit to Rs 180.45 crore in Q3 FY23 as compared with Rs 121.92 crore in Q3 FY22.
Alembic Pharmaceuticals consolidated net profit rises 48.01% in the December 2023 quarter
Sales rise 8.05% to Rs 1630.57 crore
Alembic Pharmaceuticals resumes operations at Namthang unit
Alembic Pharmaceuticals announces board meeting date
On 5 February 2024
Volumes soar at Alembic Pharmaceuticals Ltd counter
Alembic Pharmaceuticals Ltd clocked volume of 20.14 lakh shares by 14:14 IST on NSE, a 25.43 times surge over two-week average daily volume of 79174 shares

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,69,497 Cr
₹ 1,540.00
(-3.99 %)
89.67
CIPLA₹ 1,12,773 Cr
₹ 1,396.80
(-1.84 %)
34.28
DRREDDY₹ 1,01,489 Cr
₹ 6,083.85
(-1.20 %)
25.50
DIVISLAB₹ 1,00,339 Cr
₹ 3,779.70
(1.09 %)
73.55
ZYDUSLIFE₹ 96,814 Cr
₹ 962.15
(-3.22 %)
35.99

Alembic Pharmaceuticals Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Alembic Pharmaceuticals Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Alembic Pharmaceuticals Ltd's share price is ₹982.60 as of April 12, 2024

Alembic Pharmaceuticals Ltd's P/E ratio is 33.06 times as of April 12, 2024.

Alembic Pharmaceuticals Ltd's most recent financial reports indicate a price-to-book ratio of 4.37, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Alembic Pharmaceuticals Ltd's market is 19,514 Cr as on April 12, 2024.

The current financial records of Alembic Pharmaceuticals Ltd show a 11.89% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Alembic Pharmaceuticals Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Alembic Pharmaceuticals Ltd's 52-week high and low as of April 12, 2024 are ₹1004.85 and ₹977.75 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Alembic Pharmaceuticals Ltd stands at 69.61%. During the same period, Institutional Investors have shown a slight decrease in their holdings, dropping from 4.52% to 4.46%.